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The existing literature on alopecia areata (AA) clearly demonstrates patients’ concerns related to physical
symptoms, emotional well-being, mental health, social functioning, and other dimensions of daily functioning.
Although questionnaires such as the Skindex-16 and the Dermatology Life Quality Index have been used, these
questionnaires were validated for skin conditions other than AA as a chronic condition. The goals of this study
are to develop a measure of quality of life, symptoms, and their impact for patients with AA called the Alopecia
Areata Symptom Impact Scale (AASIS) and to provide psychometric evidence for its use. We used data from 1,400
patients from the National Alopecia Areata Registry together with clinical experts’ reviews and quantitative
approaches. The preliminary version of the AASIS with 13 items was administered to about 210 patients with AA.
Results indicated that the AASIS measures three underlying constructs related to AA. These dimensions were
impact of AA, hair loss, and physical skin symptoms. The internal consistency reliabilities of these subscales are
0.93, 0.86, and 0.81, respectively. Cognitive debriefing results showed that patients find the AASIS items easy to
understand, clear, and concise. Preliminary evidence suggests that the AASIS is a reliable and valid measure of the
symptoms and their impact in patients with AA.
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Patients with alopecia areata (AA) experienced profound
physiological as well as psychological and social issues
because of their unusual appearance. Physiologically, for
example, in alopecia universalis all hair on the entire head
and body is lost so that the scalp is unprotected from the sun
and elements, the eyes are unprotected from dust and glare,
and the nose and sinuses are exposed to foreign particles. As a
result, they may experience sun burn and itching of the skin.
Loss of nasal hair made them susceptible to hay fever or other
similar allergic conditions. Socially, because they look differ-
ent, adults have lost their jobs, they have been harassed, and
they have been accused of belonging to extremist cults.
Children have been moved from mainstream to special
education classes and ostracized by their peers. The existing
literature on AA clearly demonstrates patients’ concerns
related to physical symptoms, emotional well-being, mental
health, social functioning, and other dimensions of daily
functioning. Although skin disorder questionnaires such as
the Skindex-16 and health-related quality of life (HRQOL)
such as the Dermatology Life Quality Index have been used,
these questionnaires were validated for other skin conditions
but not for AA as a chronic condition. To document the
profound social, psychological, and physiological symptoms
associated with AA, a psychometrically validated tool is
necessary to collect valid and reliable information and to
assist in clinical decision-making and in research for epide-
miological studies. The goals of this study are to develop a
measure of quality of life, symptoms, and their impact for
patients with AA called the Alopecia Areata Symptom Impact
Scale (ASIS) and to provide preliminary psychometric evi-
dence for its use.
We started the development of the AASIS by identifying
the most salient symptoms and concerns related to AA. We
used HRQOL data from the National Alopecia Areata
Registry (NAAR) where about 1,400 patients responded to
the Skindex-16, Dermatology Life Quality Index, the Brief
Fear of Negative Evaluation Scale (FNES), and other HRQOL
questions totaling about 125 items. To reduce the number of
items, we used several approaches. First, clinical experts
reviewed the relevance of each HRQOL items in the NAAR.
Items deemed relevant using content validity index were
considered. Second, we examined the NAAR HRQOL items
for floor effect to remove items that were not endorsed.
Third, we used cluster analysis to identify items that were
redundant or perceived by patients to be similar. For
example, ‘‘my skin is irritated’’ may be rated similarly as
‘‘my skin itches’’ or ‘‘my skin hurts’’. A preliminary 13-item
AASIS was deemed comprehensive enough to assess
AA–related quality of life and symptoms without creating
undue patient burden.
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The preliminary version of the AASIS with 13 items was
administered to about 210 patients with AA. In response to the
Food and Drug Administration guidance in the use of patient-
reported outcomes, cognitive debriefing was performed.
Results indicated that the AASIS measures three underlying
constructs related to AA. These dimensions were impact of
AA, hair loss, and physical skin symptoms. The internal
consistency reliabilities of these subscales are 0.93, 0.86,
and 0.81, respectively. An interesting observation was that
AASIS scores were more correlated with ratings of emotional
well-being and mental well-being than physical well-being.
Cognitive debriefing results showed that patients find the
AASIS items easy to understand, clear, and concise. In
summary, preliminary evidence suggests that the AASIS is a
reliable and valid measure of the symptoms and their impact
in patients with AA. As validation is an iterative process,
further studies are needed to demonstrate other measures of
validity and reliability for the AASIS, such as known-group
validity and test–retest reliability.
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